Can Financial Statements From 2010 to 2024
| CANF Stock | 2.70 0.10 3.85% |
Check Can Fite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Can main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Can financial statements analysis is a perfect complement when working with Can Fite Valuation or Volatility modules.
Can |
Can Fite Biopharma Company Current Valuation Analysis
Can Fite's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Can Fite Current Valuation | 35.67 M |
Most of Can Fite's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Can Fite Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Can Fite Biopharma has a Current Valuation of 35.67 M. This is 99.75% lower than that of the Biotechnology sector and 99.23% lower than that of the Health Care industry. The current valuation for all Israel stocks is 99.79% higher than that of the company.
Can Fite Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Can Fite's current stock value. Our valuation model uses many indicators to compare Can Fite value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Can Fite competition to find correlations between indicators driving Can Fite's intrinsic value. More Info.Can Fite Biopharma is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Can Fite by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Can Fite's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Can Fite's earnings, one of the primary drivers of an investment's value.About Can Fite Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Can Fite income statement, its balance sheet, and the statement of cash flows. Can Fite investors use historical funamental indicators, such as Can Fite's revenue or net income, to determine how well the company is positioned to perform in the future. Although Can Fite investors may use each financial statement separately, they are all related. The changes in Can Fite's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Can Fite's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Can Fite Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Can Fite. Please read more on our technical analysis and fundamental analysis pages.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. CAN FITE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 7 people.
Pair Trading with Can Fite
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Can Fite position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Can Fite will appreciate offsetting losses from the drop in the long position's value.Moving together with Can Stock
| 0.66 | ICL | ICL Israel Chemicals | PairCorr |
| 0.66 | AZRG | Azrieli Group | PairCorr |
| 0.64 | NICE | Nice | PairCorr |
The ability to find closely correlated positions to Can Fite could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Can Fite when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Can Fite - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Can Fite Biopharma to buy it.
The correlation of Can Fite is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Can Fite moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Can Fite Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Can Fite can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Can Fite Correlation against competitors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |